Use of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Immunoglobulin in Elderly Patients

Immunotherapy - United Kingdom
doi 10.2217/imt-2019-0175
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Future Medicine Ltd

Related search

Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% in Patients With Primary Immunodeficiency Diseases: Interim Analysis of Adverse Events in a Global Post-Authorization Safety Study

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

ENHANZE® Drug Delivery Technology: A Novel Approach to Subcutaneous Administration Using Recombinant Human Hyaluronidase 20

Drug Delivery
MedicinePharmaceutical Science
2019English

Presentation and Skin Biopsy Findings in Delayed Type Hypersensitivity Reactions to Facilitated Subcutaneous Immunoglobulin Replacement

Journal of Allergy and Clinical Immunology
AllergyImmunology
2018English

Arabinosylation of Recombinant Human Immunoglobulin-Based Protein Therapeutics

mAbs
AllergyImmunology
2017English

Administration of Potassium by Subcutaneous Infusion in Elderly Patients.

BMJ
1982English

Improved Treatment Satisfaction With a New Human Subcutaneous Immunoglobulin (SCIG 20%) in Patients Previously Treated With IVIG

Journal of Allergy and Clinical Immunology
AllergyImmunology
2017English

Subcutaneous Administration of Rituximab (MabThera) and Trastuzumab (Herceptin) Using Hyaluronidase

British Journal of Cancer
Cancer ResearchOncology
2013English

Clinical Studies of Recombinant Human Granulocyte Colony-Stimulating Factor in Elderly Patients With Malignant Lymphoma.

Japanese Journal of Geriatrics
GerontologyGeriatrics
1992English

Subcutaneous Immunoglobulin in Treating Inflammatory Neuromuscular Disorders

Therapeutic Advances in Neurological Disorders
NeurologyPharmacology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy